A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients

NCT06497985 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

430

Enrollment

INDUSTRY

Sponsor class

Conditions

Colorectal Cancer

Interventions

DRUG: Tucidinostat
DRUG: Sintilimab
DRUG: Bevacizumab
DRUG: Fruquintinib

Sponsor

Chipscreen Biosciences, Ltd.